An update on anti-vascular endothelial growth factor therapy in retinal diseases
10.3760/cma.j.cn511434-20220620-00371
- VernacularTitle:眼底抗血管内皮生长因子药物应用与创新
- Author:
Wenjia YAN
1
;
Delun LUO
;
Jiajin FENG
;
Xiaoyan DING
Author Information
1. 中山大学中山眼科中心, 广州 510060
- Keywords:
Vascular endothelial growth factor;
Anti-vascular endothelial growth factor drug;
Age-related macular degeneration;
Gene therapy;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(8):701-707
- CountryChina
- Language:Chinese
-
Abstract:
Vascular endothelial growth factor (VEGF) is a multifunctional factor that promotes blood vessel formation and increases vascular permeability. Its abnormal elevation plays a key role in common retinal diseases such as wet age-related macular degeneration and diabetic macular edema. Anti-VEGF therapy can inhibit angiogenesis, reduce vascular leakage and edema, thereby delaying disease progression and stabilizing or improving vision. Currently, the clinical application of anti-VEGF drugs has achieved satisfactory therapeutic effects, but there are also issues such as high injection frequency, heavy economy burden, potential systemic side effects, and non-responsiveness. To address these issues, current research and development mainly aim on biosimilars, multi-target drugs, drug delivery systems, oral anti-VEGF drugs, and gene therapy. Some drugs have shown great potential and are expected to turn over a new leaf for anti-VEGF treatment in ophthalmology.
